INS and chronic kidney disease: However, the National Institute for Health and Care Excellence advised the use of sotagliflozin in 2020 for T1 DM patients when insulin alone is insufficient to control glycemia.[21] Another agent, Pramlintide can be used if renal functions are normal but limited experience is available regarding its use in CKD and is therefore not recommended in this subset of patients.